Status:
UNKNOWN
Q10 Preloading Before Cardiac Surgery for Kidney Failure Reduction
Lead Sponsor:
Clinical Hospital Center, Split
Conditions:
Acute Kidney Injury
Acute Kidney Failure
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Coenzyme Q10 (CoQ10) is an essential molecule in human body. It acts as an antioxidant, a co-factor for energy conversion in mitochondria and has anti-inflammatory effects capable of improving endothe...
Eligibility Criteria
Inclusion
- Adult patients scheduled for elective cardiac surgery
Exclusion
- patients receiving high dose vitamin B supplementation (defined as more that 200% of recommended daily allowances)
- patients under warfarin therapy
- urgent surgery
- end stage kidney disease
- therapy with multiple nephrotoxic drugs
- chronic kidney disease
- obstructive uropathy
- previous cardiac surgery procedure
- alcohol abuse
- malignancy
- allergy to any ingredient of Myoqinon capsule
- patients receiving Myoqinon and fail to demonstrate a significant increase in blood concentration of Q10
- uncontrolled hypertension
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04445779
Start Date
July 15 2020
End Date
December 1 2021
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Center Split
Split, Split-Dalmatia County, Croatia, 21000